Inhibitors of type 2 vascular endothelial growth factor receptors
AssigneeBristol-Myers Squibb Company
InventorsYan CHEN, Elena GETMANOVA, Martin C. WRIGHT, Alan S. HARRIS, Ai Ching LIM, Jochem GOKEMEIJER, Lin SUN, Michael WITTEKIND
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
Claims21
1-6. (canceled)
A polypeptide comprising a fibronectin type III tenth (10Fn3) domain, wherein the 10Fn3 domain (i) comprises a modified amino acid sequence in one or more of the AB, BC, CD, DE, EF and FG loops relative to the wild-type 10Fn3 domain set forth in SEQ ID NO:
- 5, (ii) binds to a target molecule not bound by the wild-type 10Fn3 domain, and (iii) comprises a C-terminal tail comprising the sequence EIDKPXQ, wherein X is C or S.
A polypeptide comprising a fibronectin type III tenth (10Fn3) domain, wherein the 10Fn3 domain (i) has a deletion or mutation of 1 to 8 amino acids in the N-terminus of the wild-type 10Fn3 domain set forth in SEQ ID NO:
- 5, (ii) comprises a modified amino acid sequence in one or more of the AB, BC, CD, DE, EF and FG loops relative to the wild-type 10Fn3 domain, and (iii) binds to a target molecule not bound by the wild-type 10Fn3 domain.
A polypeptide comprising a fibronectin type III tenth (10Fn3) domain, wherein the 10Fn3 domain (i) comprises a modified amino acid sequence in one or more of the AB, BC, CD, DE, EF and FG loops relative to the wild-type 10Fn3 domain, (ii) binds to a target molecule not bound by the wild-type 10Fn3 domain;
- and (iii) binds to the target molecule from a first mammal and to a homolog thereof from a second mammal.
Dependencies are inferred from the claim text.